This article is more than 5 years old. Information may no longer be current.

Kala posts quarterly loss

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Kala Pharmaceuticals reported a net loss of $11.3 million in the first quarter of 2018 compared with a net loss of $9.8 million in the same time period of 2017, according to a company press release.

General and administrative expenses increased from $1.5 million in 2017’s first quarter to $5.5 million this year, while research and development expenses decreased from $8 million to $5.7 million.

The company had cash of $100.5 million as of March 31.